This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: BIIB Up on AD Data, ALXN to Buy ACHN & Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week include acquisition news, and regulatory and pipeline updates.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge
Biogen (BIIB) Up 40% on Alzheimer's Drug & More
by Mark Vickery
This is about as "game changer" as a drug can get, at least in the early stages.
Biogen (BIIB) Beats on Q3 Earnings, Eyes FDA Nod for Aducanumab
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.
Biogen (BIIB) Q3 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the third quarter. It is set to pursue FDA approval of aducanumab. Shares skyrocket in pre-market trading.
Earnings Surprise May Lift Stocks: Buy These Growth ETFs
by Sweta Killa
Market participants are betting on the record-high U.S. indices as about 120 S&P 500 companies are scheduled to release their results this week.
Biogen (BIIB) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Biogen's (BIIB) MS franchise sales are expected to have been soft in the third quarter of 2019. Spinraza U.S. sales are expected to have been supported by continued patient growth
Biogen Strengthens MS & SMA Portfolio as Competition Lurks
by Zacks Equity Research
Biogen strengthens existing efforts in multiple sclerosis and spinal muscular atrophy while making efforts to foray into other neuroscience areas. However, MS is a competitive space. Spinraza may soon face competition.
The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon Communications, PepsiCo, Biogen, Bank of New York ??? Mellon and Cerner
Top Stock Reports for Verizon, PepsiCo & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications (VZ), PepsiCo (PEP) and Biogen (BIIB).
Biotech Stock Roundup: Pipeline Updates From REGN, BIIB, AMGN and More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, licensing deals, and more.
Biogen's Two MS Drugs Get CHMP Nod for Use in Pregnancy
by Zacks Equity Research
Biogen (BIIB) gets CHMP's recommendation to remove pregnancy contraindications from labels of interferon beta treatments, including Plegridy and Avonex
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Sweta Killa
Sector ETF report for PBE
Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
by Zacks Equity Research
Biogen (BIIB) starts a DEVOTE study to investigate whether a higher dose of Spinraza can provide greater efficacy for treating patients with spinal muscular atrophy.
Alexion (ALXN) Down on News of CFO Clancy's Departure in 2019
by Zacks Equity Research
Alexion's (ALXN) shares decline, following the news of the departure of its current chief financial officer, Paul Clancy.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Roche's Gazyva Now a Breakthrough Therapy for Lupus Nephritis
by Zacks Equity Research
Roche's (RHHBY) lymphoma drug, Gazyva, obtains Breakthrough Therapy designation in the United States for lupus nephritis.
The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Crocs, Casey's General Stores and Clean Harbors
Biogen Stops Late-Stage Studies on Alzheimer's Candidate
by Zacks Equity Research
Biogen (BIIB) and its Japanese partner, Eisai receive another setback as they discontinue two late-stage studies evaluating elenbecestat in patients with Alzheimer's disease.
What September Doldrums? Here's Why Stocks Are Moving Higher
by Tirthankar Chakraborty
From ECB stimulus to trade optimism, all are helping stocks eke out gains. And let's admit that recession may be coming, but it isn't around the corner.
Top 5 ROE Stocks to Profit as Sino-US Trade Tensions Abate
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Amgen's KRAS Inhibitor Shows Response in Larger NSCLC Group
by Zacks Equity Research
Amgen's (AMGN) novel investigational KRAS inhibitor, AMG 510, for solid tumor shows anti-tumor activity in a larger group of NSCLC patients.
5 Price-to-Book Value Picks for September
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Novartis Inks Commercialization Deal for Tysabri Biosimilar
by Zacks Equity Research
Novartis' (NVS) generics unit, Sandoz, inks deal with Polpharma Biologics for a proposed natalizumab biosimilar for the treatment of RRMS.
Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies
by Zacks Equity Research
Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.